Skip to content
10-K

Annual Report

REGENXBIO Inc. RGNX

0000950170-25-038770

← back to feed
Filed
Mar 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 7, 2025 50.09M sh
Cost Of Revenue FY 2024 · Dec 31, 2024 $33.57M
Cost Of Revenue FY 2024 · Dec 31, 2023 $37.21M
Cost Of Revenue FY 2024 · Dec 31, 2022 $54.55M
Shares Diluted FY 2024 · Dec 31, 2023 43.73M sh
Shares Diluted FY 2024 · Dec 31, 2022 43.15M sh
Capex FY 2024 · Dec 31, 2023 $9.96M
Capex FY 2024 · Dec 31, 2022 $30.72M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$218.41M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$207.49M
Cash And Equivalents FY 2024 · Dec 31, 2023 $34.52M
Cash And Equivalents FY 2024 · Dec 31, 2022 $96.95M
Current Liabilities FY 2024 · Dec 31, 2023 $130.27M
Total Liabilities FY 2024 · Dec 31, 2023 $262.23M
Current Assets FY 2024 · Dec 31, 2023 $334.97M
Total Assets FY 2024 · Dec 31, 2023 $573.97M
Eps Diluted FY 2024 · Dec 31, 2023 −$6.02
Eps Diluted FY 2024 · Dec 31, 2022 −$6.50
Eps Basic FY 2024 · Dec 31, 2023 −$6.02
Eps Basic FY 2024 · Dec 31, 2022 −$6.50
Sga Expense FY 2024 · Dec 31, 2023 $88.49M
Sga Expense FY 2024 · Dec 31, 2022 $85.28M
Rd Expense FY 2024 · Dec 31, 2023 $232.27M
Rd Expense FY 2024 · Dec 31, 2022 $242.45M
Net Income FY 2024 · Dec 31, 2023 −$263.49M
Net Income FY 2024 · Dec 31, 2022 −$280.32M
Operating Income FY 2024 · Dec 31, 2023 −$268.13M
Operating Income FY 2024 · Dec 31, 2022 −$262.88M
Revenue FY 2024 · Dec 31, 2023 $90.24M
Revenue FY 2024 · Dec 31, 2022 $112.72M
Stockholders Equity FY 2024 · Dec 31, 2022 $516.2M
Stockholders Equity FY 2024 · Dec 31, 2021 $764.3M